Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 ...
Denmark: A recent exploratory analysis published in Clinical Obesity has found that liraglutide, a GLP-1 receptor agonist ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...
Introduction to the Global Respiratory Diagnostics MarketThe global respiratory diagnostics market is projected to expand at a steady growth rate of approximately 7% over the next five years, ...
CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a ...
April 2026 has brought one of the harshest Chiang Mai haze periods of the season. On April 4, PM2.5 reportedly spiked to 409 ug/m3 at Nakornping Hospital in ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...
The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...
AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help ...
After receiving dupilumab vs. topical corticosteroid or prednisone for up to 24 months, the risk for alopecia areata ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results